| Therapeutic | Golimumab |
| Target | TNFA |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK |
| 100% seqID Fv Structure | 5yoy [Fvs: GD, HE, IF, PM, QN, RO] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5yoy [Fvs: GD, HE, IF, PM, QN, RO] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | Medarex UltiMAb Mouse |
| INN Year Proposed | 2004 |
| INN Year Recommended | 2005 |
| Companies Involved | Centocor, Centocor Ortho Biotech, Janssen Biotech, Merck & Co, Mitsubishi Tanabe Pharma Corporation, Medarex |
| Conditions Approved | Ankylosing spondylitis, Juvenile rheumatoid arthritis, Non-radiographic axial spondyloarthritis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis |
| Conditions Active | Hearing disorders, Type 1 diabetes mellitus |
| Conditions Discontinued | Asthma, Cardiovascular disorders, Sarcoidosis, Uveitis |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
